163 results about "Gastrointestinal disorder" patented technology

The invention provides a gastrointestinal tract disease postoperative rehabilitation method and system based on big data, and relates to the technical field of gastrointestinal tract postoperative rehabilitation, historical rehabilitation patient data is acquired and clustered, historical rehabilitation patient clustering results and disease cluster similarities corresponding to different types of gastrointestinal tract disease clusters in the clustering results are acquired, and the disease cluster similarities are obtained; generating a gastrointestinal tract disease candidate set based on the disease cluster similarity, fusing a preset gastrointestinal tract disease standard vector with the gastrointestinal tract disease candidate set based on a gastrointestinal tract constraint fusion mechanism to generate a gastrointestinal tract disease rehabilitation prediction curve, and constructing a recombinant gastrointestinal tract disease candidate set; performing threshold calculation based on the recombinant gastrointestinal disease candidate set to obtain a dynamic threshold, obtaining a real-time data vector of a to-be-rehabilitated patient, matching a corresponding gastrointestinal disease rehabilitation prediction curve, comparing the real-time data vector of the to-be-rehabilitated patient with the gastrointestinal disease rehabilitation prediction curve, and implementing a corresponding strategy based on a comparison result. The method can assist a physician in generating a treatment scheme.

The invention discloses a triggering probiotic-drug conjugate and a preparation method and application thereof, and belongs to the technical field of oral drug delivery systems, the triggering probiotic-drug conjugate comprises probiotics, an adhesive inner layer formed by coordination of tannic acid and Fe < 3 + >, and an outer layer formed by pterostilbene-phospholipid bridged by ROS-responsive thioether bonds and cholesterol; the inner layer coats the surfaces of the probiotics through coordination, and the outer layer coats the outer part of the inner layer through self-assembly. An outer lipid layer is decomposed under high-concentration ROS in an inflammation colon area, and probiotics coated with pterostilbene and a tannic acid layer are released. Pterostilbene relieves inflammation and rebuilds a pathological microenvironment, and catechol groups in a tannic acid layer and the surface of the intestinal tract generate multiple interactions to promote planting of probiotics. In UC mouse models, the conjugates exhibit enhanced therapeutic effects by inhibiting inflammation, restoring intestinal barrier function, and improving intestinal microbiota homeostasis. The invention has important transformation potential in clinical application of gastrointestinal diseases.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The invention belongs to the technical field of medical image processing, and provides a multi-modal medical image analysis system, medium and equipment for gastrointestinal disease recognition, and the technical scheme is as follows: extracting multi-scale texture features and structural features of a gastrointestinal endoscopy color image and a gastrointestinal endoscopy OCT depth image respectively, and fusing to obtain a cross-modal feature sequence; based on the feature sequence added with the position code, learning a spatial corresponding relation of different modal data on blood vessel morphology and gastrointestinal tract wall interlayer structure; obtaining a multi-scale global context feature sequence and a local detail feature sequence based on the aligned cross-modal blood vessel and gastrointestinal tract wall interlayer structure features, and fusing the multi-scale global context feature sequence and the local detail feature sequence to obtain fused multi-modal features; obtaining an adjusted dense deformation field based on the fused multi-modal features; and performing coarse registration and fine registration based on the adjusted dense deformation field to obtain a registered gastrointestinal endoscopy color image and a registered gastrointestinal endoscopy OCT depth image. The anti-interference capability is strong, and the data stability is high.

The invention discloses a magnetic control soft robot with electrical stimulation and drug release functions, and relates to the technical field of medical instruments. In the magnetic control soft robot provided by the invention, the magnetic layer is used for driving the body to move and position in the gastrointestinal tract under the driving of an external magnetic field; the electric control layer is used for supplying power and is responsible for controlling the opportunity and parameters of electric stimulation and controlling a drug release instruction; after a microneedle of the conductive hydrogel microneedle layer penetrates into tissue, nerve endings or muscle cells can be stimulated by applying a weak electric signal so as to regulate gastrointestinal motility, relieve pain and the like, a drug can be loaded in the microneedle, and when the electric signal is applied, the drug can be loaded in the microneedle by means of electromigration, electroosmosis and the like. Triggering the drug to be controllably released into the target tissue as required; the adhesive layer is used for temporarily anchoring the robot at a specific working position of the gastrointestinal tract; according to the magnetic control soft robot and the preparation method thereof, the comprehensive requirements of gastrointestinal tract disease treatment can be met.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in a cell or subject, and in certain instances reducing the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, a Developmental and Epileptic Encephalopathy, an intellectual disability, or an autism spectrum disorder. Such symptoms and hallmarks include, but are not limited to seizures, hypotonia, sensory integration disorders, motor development delays and dysfunctions, intellectual and cognitive dysfunctions, movement and balance dysfunctions, visual dysfunctions, delayed language and speech, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.

The present invention relates to a system for monitoring gastrointestinal disorders, the system including a gastrointestinal probe, at least one sensor configured to measure a patient parameter, a patient interface configured to receive input from the patient, and a processor configured to: determine a first value and a second value corresponding to a given time interval, where if the input from the patient corresponds to the given time interval, the first value is determined based on a measurement of the parameter corresponding to the given time interval and based on the input from the patient corresponding to the given time interval, and the second value is determined based on a measurement of gastroesophageal contents corresponding to the given time interval; and determine a level of gastrointestinal disorders based on the set of determined value pairs.

Disclosed herein are methods for administering a dose of a microbiota recovery therapy composition by colonoscopy. The methods disclosed herein are useful for the treatment of diseases and / or conditions of the digestive tract, such as Clostridium difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method can result in improved quality of life. These methods are capable of altering the gut microbiota composition and / or the gut metabolome composition. The microbiota recovery therapy composition comprises a fecal microbiota suspension comprising: a fecal microorganism derived from a human fecal sample, and a solution of polyethylene glycol and brine.

A method for treating a gastrointestinal condition includes preparing an aqueous extract of bioactive compound by adding dried green tea material to hot water and filtering the aqueous extract; adding a solution of an iron-containing compound to the filtered aqueous extract to form a complex or chelate of the bioactive compounds with iron; and drying the solution at a temperature between 80 to 150 degrees Fahrenheit to obtain a fine granular or powdered state.

This invention discloses a classification method and system for gastrointestinal diseases based on convolution and state-space models. The classification method includes extracting texture features from medical images of gastrointestinal diseases, determining lesion regions in the medical images based on the texture features, adaptively enhancing the contrast of the lesion regions, performing preprocessing, and inputting the preprocessed features into the patch embedding module of a trained deep learning model to segment the medical image into multiple patches. The patches are then sequentially input into two fusion modules, where the convolutional units and state-space units of each fusion module extract local and global features from the patches, respectively, and then fuse the local and global features. A patch merging module is used to merge the fused features of multiple patches, and the merged features are input into the two fusion modules of the deep learning model to generate fused features of the merged features. The previous step is repeated a preset number of times to obtain the final feature map, which is then input into the classifier of the deep learning model to obtain the classification result.

A method for treating conditions of the gastrointestinal tract of a subject using a vibrating ingestible capsule ingested by the subject and activated in a targeted zone of the gastrointestinal tract of the subject. The conditions may include a sensation of gastric bloating, a sensation of straining during defecating, diarrhea and / or gastroparesis. The method is further suitable for reducing Bristol stool scores of fecal matter of the subject and for increasing a Bristol stool score of fecal matter of the subject.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

Described are methods of treating neurodegenerative disease by administering a therapeutically effective amount of fenchol to a patient in need thereof. Additionally, described are methods of activating FFAR2 signaling in a patient by administering a therapeutically effective amount of fenchol to a patient in need thereof. Methods of treating gastrointestinal disorders in a patient being treated for cancer and methods of improving cognition in a patient being treated for cancer are also described. Further, the present disclosure provides for a pharmaceutical composition including fenchol and an Alzheimer's disease drug. Additionally, a nasal spray including fenchol, a buccal tablet including fenchol, and a dietary supplement including fenchol are described.

Methods of treating, reducing the risk of, preventing, or alleviating a symptom of inflammation or inflammatory gastrointestinal disease by administration of a modified bacterium providing purines, in particular hypoxanthine, to the mucosa of the intestine, and compositions containing modified bacteria useful in such methods.

The present invention relates to a pharmaceutical composition for the prevention or treatment of gastrointestinal diseases, comprising a therapeutically effective amount of a compound represented by chemical formula 1, wherein provision is made of dosages and administration regimens of the composition suitable for achieving optimal prophylactic and therapeutic effects in a subject with a gastrointestinal disease. [Chemical formula 1]

The utility model provides a nutrition supply pump special for patients with gastrointestinal diseases, and relates to the technical field of medical instruments. A control key and a display screen are arranged on one side of the instrument panel, and a boss is arranged on the other side of the instrument panel; according to the nutrition supply pump, a sectional infusion tube is adopted, a second tube section is clamped in a first clamping groove and a second clamping groove of an instrument panel and is clamped in a warmer after penetrating through a penetrating hole, nutrient solution is heated through the warmer before infusion, a movable connector at the tail end of the second tube section is connected with a third tube section, and the tail end of the third tube section is connected with the nasal cavity or the intestinal tract of a patient; before use, one end of the first pipe section is inserted into a nutrient solution, and the other end of the first pipe section is connected with the movable connector at the head of the second pipe section, so that the household nutrient solution supply pump has the advantages of being inserted and used at any time and convenient to use under the condition that spread of infectious diseases among different patients or large ingredient change of the nutrient solution every time does not need to be considered; the problem that an infusion tube is inconvenient to install in an existing nutrition supply pump is solved.

The disclosure generally relates to ready to drink electrolyte solution. In particular the disclosure relates to a ready to drink electrolyte solution comprising isomaltulose, glucose, sodium ions, chromium ions and water; wherein the glucose concentration is greater than or equal to 0.9g / 100ml, and wherein the theoretical glycemic index of the solution is equal to or less than 55. The disclosure also relates to a method of manufacturing said ready to drink electrolyte solution. The disclosure also relates to a method of rehydrating a patient suffering from cancer, diabetes, acute or chronic illness, or a gastrointestinal disorder by using said ready to drink electrolyte solution.

To provide a system and a method for easily and accurately detecting a defecation event and acquiring defecation event data.SOLUTION: A system 100 and a method facilitate detection and recording of a defecation event of a target such as a participant of a clinical test for treating a digestive system disease such as an irritable bowel syndrome (IBS), an inflammatory bowel disease (IBD), and chronic coprostasis. The system 100 and the method can be used by individual patients for detecting and recording a defecation event, and resultant data can be checked in detail by a medical treatment provider at the time of evaluating health and / or treatment of the gastrointestinal of the patient.SELECTED DRAWING: Figure 1

This disclosure provides a method for treating a disease in a subject requiring treatment, such as chronic pain or IBS-D, the method of treating the disease by orally administering i) a therapeutically effective amount of buprenorphine dimer, or ii) a pharmaceutical composition comprising a therapeutically effective amount of buprenorphine dimer, wherein the buprenorphine dimer is represented by formula (I) or a pharmaceutically acceptable salt thereof. In particular, the administered buprenorphine dimer of formula (I) is in a neutral form. A method for producing a neutral form of buprenorphine dimer is also described.

The disclosure relates to pharmaceutical formulations and method of using chymase inhibitors for the prevention and treatment of mast cell-related disease states in which chymase is involved. More particularly the present disclosure is in the field of treating or preventing or reducing the symptoms of mast cell-related diseases, including atopic dermatitis (AD), chronic urticaria (CU), Eosinophilic Gastrointestinal Disorders (EGIDs), and prurigo nodularis (PN), using a chymase inhibitor, including a chymase inhibitor that prevents cleavage of stem cell factor (SCF) and its interaction with receptor tyrosine kinase (c-kit), thereby reducing mast cell activation and proliferation.

To provide peptides and compositions useful for treatment of gastrointestinal disorders or for colon cleansing.SOLUTION: The present invention provides compositions and methods of treating gastrointestinal disorders as well as pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. The present invention features peptides, compositions and related methods for colon cleansing treatment as well as other conditions and disorders described herein. In one embodiment, the peptides may be used to prepare subjects for colonoscopy treatment. In some embodiments, the peptides or pharmaceutically acceptable salts may be used to prepare subjects for surgery, such as bowel surgery.SELECTED DRAWING: None

In some embodiments, a composition comprising Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus plantarum, and Streptococcus thermophilus is provided. In some embodiments, provided is the use of a composition of any of the examples herein for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorder (ASD), anxiety disorder and / or gastrointestinal (GI) disorder or condition, enhancing attention and / or concentration, or stimulating a GABA receptor in a subject. In some embodiments, methods and kits are provided for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorders, anxiety disorders, and / or gastrointestinal disorders or conditions, enhancing attention and / or concentration, or stimulating GABA receptors in a subject. In certain embodiments, the compositions are safe to use and effective to prevent or alleviate anxiety and / or sensory hypersensitivity in subjects, particularly children subjects.

The present invention relates to the field of therapeutic compositions for gastrointestinal disorders. More particularly, the invention refers to compositions comprising resveratrol, saffron extract and vitamin D, and to the use thereof for the treatment of functional gastrointestinal disorders, and in particular for the treatment of irritable bowel syndrome (IBS).

Embodiments of the present disclosure relate to the technical field of medical data processing, and specifically to a nutritional preparation medication information processing method, device, equipment and medium. The main steps of the foregoing method include: in response to an audit request for a medication prescription, retrieving and obtaining clinical diagnosis data corresponding to the medication prescription, extracting a disease keyword from the clinical diagnosis data, matching and analyzing the disease keyword with preset parenteral nutrition indication information to obtain a matching result, when the matching result indicates a matching success, auditing the medication prescription according to a first medication standard, and when the matching result indicates a matching failure, determining a second medication standard according to a nutritional risk score, gastrointestinal disorder information and a preset decision matrix, and auditing the medication prescription according to the second medication standard. The foregoing method can improve the efficiency of prescription auditing, improve the accuracy and rationality of the nutritional preparation medication prescription audit result, and reduce the medication risk of the nutritional preparation medication prescription.

The invention discloses application of a dibenzo nitrogen heterocyclic compound in preparation of a medicine for treating gastrointestinal diseases, and relates to the technical field of medicinal chemistry. A large amount of screening and verification show that the dibenzo nitrogen heterocyclic compound with the structural general formula can significantly reduce core pathological characteristics of gastric ulcer, such as significant reduction of ulcer lesion, significant reduction of bleeding degree and specific reduction of mucosal edema, and has an ulcer inhibition rate of 36.51%-47.22% for a gastric ulcer animal model. A new thought and a new choice are provided for the development of medicines for treating gastrointestinal diseases.

The present disclosure provides a method of treating a disease (e.g., chronic pain or IBS-D) in a subject in need thereof by oral administration: i) a therapeutically effective amount of buprenorphine dimer; or ii) a pharmaceutical composition comprising a therapeutically effective amount of the buprenorphine dimer wherein the buprenorphine dimer is represented by Formula (I): or a pharmaceutically acceptable salt thereof, in particular, the administered buprenorphine dimer of Formula (I) is in a neutral form, methods of preparing the buprenorphine dimer in neutral form are also described.

The invention relates to 1,5-benzothiadiazepine and 1,2,5- benzothiadiazepine derivatives of formula (1). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, liver diseases and renal diseases.

Methods and compositions for treating and / or preventing gastrointestinal disorders and / or improving digestive comfort in an individual in need thereof, the composition comprising a low sugar, low lactose, milk-based composition comprising galactooligosaccharide (GOS).